PublicPrivate Partnerships in a Time of Crisis

1
Public/Private Partnerships in a Time of Crisis

• Geoff Mitchinson
• Vice-President, Commercial and Corporate Affairs
• GlaxoSmithKline Canada

2
Overview

• GSK Partner or Supplier?
• Integrating and Adapting to Technology

3
GlaxoSmithKline Who are we?

• International research-based pharmaceutical
  company
• 1 provider of vaccines in the world, 1 flu
  manufacturer in Canada
• 5 billion in RD, 176M in Canada
• Over 100,000 people in over 140 countries
• 2,800 in Canada
• Therapeutic Areas

4
Supplier or Partner?

• Addressing the healthcare challenges of the
  developing world requires an innovative,
  responsible and, above all, sustainable approach.
  
• Preferential pricing
• Research and development
• Community investment and partnerships
• Innovative partnerships and solutions

5
The Challenge of Pandemic

• Government/Public Sector
• Significant health threat and societal disruption
• Planning for the unknown
• Political pressure on decision making
• Industry/Private Sector
• Developing expertise and product
• Establishing commercial viability
• Engaging in decision making

Partnerships are key to managing risk
6
Medical Interventions
VACCINE Provides immunity by causing the
production of antibodies against the vaccine
virus. To produce a pandemic vaccine, the
specific strain is required.
ANTIVIRALS Reduces the virus ability to
reproduce. Virus-specific intervention at
pandemic onset. Prevention and Treatment
7
GSK and Influenza
VACCINES Pandemic Vaccine
ANTIVIRAL Relenza
8
Advancing Vaccines

• With IDB
• Canadian government engaged industry to develop
  increased and sustained vaccines capacity
• Manufacturing capability
• RD in Flu technology
• Contractual obligations for supply
• With GSK
• Opportunity to continually evolve

9
Technology Driven Strategies
World-wide H5N1 Pandemic
Phase 4
Phase 5
Phase 6 PANDEMIC
Pre-Pandemic
Month 6
6 Months
Pre-Pandemic vaccine
Pandemic vaccine
10
Evolving Role for Antivirals

• At launch
• Flu is not a serious condition
• Inability to administer within 48 hours
• Little to no demand
• Today
• Threat of a pandemic has sparked interest
• High demand for large quantities
• Need for ramped up capacity and ongoing research

11
Case Study USA

• Proactive and aggressive approach to pandemic
  investment
• The US Department of Health and Human Services
  has
• Stockpiled antivirals based on population
• Diversified antivirals to protect against
  potential resistance
• Stockpiled bulk H5N1 antigen for potential
  formulation
• Announced purchase of pre-pandemic vaccine using
  proprietary adjuvant systems
• Invested in advancing cell-culture research
• Identified funds to assist with outbreaks in
  other countries

12
Challenges for the Private Sector

• Public sector cannot fully address business
  continuity issues
• Private sector is seeking guidance from industry
• How do I plan?
• How do I protect employees?
• Should I purchase antivirals?
• How much do I need?
• Where do I purchase and store antivirals?
• How do I distribute and administer antivirals?

Partnerships are key to managing risk
13
In summary

• GSK is a global company with expertise in complex
  health challenges
• Pandemic preparedness requires a collaborative
  and collective response in which government and
  industry need to partner
• Key to success is the ability to integrate and
  adapt to advancements in technology, science and
  knowledge